Generic Name and Formulations:
Olanzapine 10mg/vial; IM inj after reconstitution.

Company:
Lilly, Eli and Company
Indications for ZYPREXA INTRAMUSCULAR:
Agitation due to bipolar I mania.

Adult:
Give by deep IM inj. Usual range: 2.5mg–10mg/dose. Elderly: 5mg. Debilitated, risk of hypotension, or sensitive to olanzapine: 2.5mg. All: up to 3 doses daily (2–4 hrs apart); switch to oral form when appropriate. Severe orthostatic hypotension: not recommended.

Children:
Not recommended.

Contraindications:
Combination therapies: see other drug monographs.

Warnings/Precautions:
Relprevv: post-injection delirum/sedation syndrome: monitor after each injection. Elderly (not for dementia-related psychosis; may increase risk of death). Cardio- or cerebrovascular disease. Diabetes. Monitor for hyperglycemia, hyperlipidemia; do fasting blood glucose and lipids testing at beginning, and during therapy. Monitor for weight gain. Hypovolemia. Dehydration. History of seizures. Conditions that affect metabolism or hemodynamic responses. Hepatic impairment (monitor ALT/AST). GI or GU obstruction. Narrow angle glaucoma. History of paralytic ileus or breast cancer. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Strenuous exercise. Exposure to extreme heat. Reeva luate periodically. Dysphagia. Suicidal ideation (monitor). Write ℞ for smallest practical amount. Debilitated. Labor & delivery. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:
Orthostatic hypotension with antihypertensives, alcohol, benzodiazepines, others. Avoid alcohol. Caution with other CNS drugs, drugs that lower seizure threshold, anticholinergics, and with hepatotoxic agents. May antagonize levodopa, dopamine agonists. May be antagonized by rifampin, omeprazole, carbamazepine, others that induce CYP1A2 or glucuronyl transferase. May be potentiated by fluvoxamine, others that inhibit CYP1A2. Smokers may have increased metabolism.

See Also:
ZYPREXA

ZYPREXA ZYDIS

Pharmacological Class:
Thienobenzodiazepine.

Adverse Reactions:
Somnolence, sedation, dizziness, constipation, weight gain, personality disorder, akathisia, asthenia, rhinitis, postural hypotension, tachycardia, headache, fever, abdominal pain, diarrhea, vomiting, dry mouth, cough, nasopharyngitis, nervousness, joint pain, peripheral edema, hyperglycemia, tardive dyskinesia, worsening of parkinsonian symptoms, neuroleptic malignant syndrome (monitor), hyperprolactinemia, increased ALT; leukopenia, neutropenia, agranulocytosis; others.

How Supplied:
Tabs—30; Zydis—30; Vial—1